Wednesday, September 26, 2018 2:36:59 PM
3D Signatures Inc (C:DXD) ()OTC:TDSGF)
Shares Issued 46,445,199
Last Close 5/30/2018 $0.155
Tuesday September 25 2018 - News Release
Mr. Hugh Rogers reports
3D SIGNATURES INC. APPOINTS NEW CEO
3D Signatures Inc. has appointed Dr. Sherif Louis, PhD, as the company's chief executive officer.
Dr. Louis is an accomplished scientist and experienced leader in the biotechnology industry. Dr. Louis was an early key contributor to the development of the company's 3-D telomere technology and TeloView software platform dating back almost 15 years. He has held various leadership and executive positions with Canadian non-profit orgaizations focused on advising and coaching for-profit biotech enterprises engaged in technology commercialization. Dr. Louis has also served on the board of directors of the Biotechnology Association of Manitoba. Dr. Louis formaly joined 3D Signatures in September, 2015, and most recently held the position of director of clinical operations.
"I am a true believer in the power of the TeloView software platform. I know the science intimately and I look forward to refocusing the company on large commercial opportunities in collaboration with strategic partners," said Dr. Louis.
"Dr. Louis is dedicated to delivering shareholder value through prudent allocation of company resources. 3DS will focus on opportunities that provide leverage through academic, clinical and industry partnersnips. We are confident that Dr. Louis is the right person to lead operations during this critical transition," said Hugh Rogers, interim chair.
About 3D Signatures Inc.
3D Signatures is a personalized medicine company with a proprietary software platform, TeloView, that is designed to predict the course of certain diseases and to tailor treatment options for the individual patient. The technology is based on the 3-D analysis of telomeres, the protective caps at the ends of chromosomes.
We seek Safe Harbor.
© 2018 Canjex Publishing Ltd.
FEATURED Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical Market • Mar 18, 2024 8:51 AM
FEATURED Prospera Energy Inc. Announces a 508% increase in the 2023 Proven Developed Producing (PDP) Reserve Valuation • Mar 18, 2024 8:09 AM
Greenlite Ventures Enters into Strategic Alliance with Woodway USA • GRNL • Mar 15, 2024 4:00 PM
HealthLynked Welcomes David Rosal as New Chief Financial Officer • HLYK • Mar 13, 2024 8:00 AM
ECGI Holdings, Inc. Announces Continued Efforts in Financial Optimization • ECGI • Mar 13, 2024 8:00 AM
PSYC Begins Business Overhaul Process with Consolidation of 10 Previously Issued Convertible Debentures • PSYC • Mar 13, 2024 7:13 AM